Email

xchen@um.edu.mo

Tel

(853) 8822 4513

Office

N22-9003

Consultation Hours

Wed: 16:00-17:00
Thu: 09:00-10:10

 

Secretary to the Director

Sherry, Wai-San Wong(Ms), N22-9003
Tel: (853) 8822 4622
Fax: (853) 2884 1358
Email: waisanwong@um.edu.mo

Xin CHEN 陳新

Distinguished Professor
Director, Institute of Chinese Medical Sciences
Director, State Key Laboratory of Mechanism and Quality of Chinese Medicine (University of Macau) [SKL-MQCM (UM)]

Academic Qualifications

  • PhD, Radboud University Nijmegen
  • MD, Guangzhou University of Chinese Medicine
  • Msc, Hubei University of Chinese Medicine
  • BSc, Hubei University of Chinese Medicine

Teaching

HSCI3009Chinese Medicine
GEGA1004Global History of Medicine
GEST2003Exploring Chinese Medicine

Research Interests

  • Chinese medicine: cellular and molecular basis of immunoregulatory effect of Chinese medicine
  • Immunology: Biological and pharmacological regulation of CD4+FoxP3+ regulatory T cells (Tregs)
  • Translational research: development of novel immunotherapy and Chinese medicine-derived therapeutics for the treatment of cancer and autoimmunity

From 1991 to 1998, Dr. Chen was a research physician at the Shenzhen Institute of Integrative Chinese and Western Medicine, Shenzhen Red Cross Hospital (Shenzhen 2nd People’s Hospital). In 1998, Dr. Chen decided to change his fields of research from clinically-orientated studies to fundamental laboratory research in immunology using his strong background of alternative medicines. Dr. Chen started his Post Doctoral training at the School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK. In April of 1999, Dr. Chen joined the Laboratory of Molecular Immunoregulation, National Cancer Institute (NCI)-Frederick, NIH, USA, as a Visiting Fellow. In 2001, Dr. Chen became a Scientist II in the Laboratory of Molecular Immunoregulation, Basic Science Program, SAIC-Frederick, Inc., NCI-Frederick. From 2011 to 2014, he was a Senior Scientist in the same group. In October of 2014, He joined the University of Macau. Now he is a Distinguished Professor of Biomedical Sciences at State Key Laboratory of Mechanism and Quality of Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China

  • Chen, X.* as corresponding author or co-corresponding author
  • Orcid: 0000-0002-2628-4027
  • Total citation: 7469 (WOS); 11179 (Google Scholar)
  • H-index: 46 (WOS); 50 (Google Scholar) (2025.6.10)
  1. Wang, Z.; Xu, D.; Chen, X.*, Rigorous clinical trials for traditional Chinese herbal medicine: Challenge and opportunity. Innov Med, 2025, 3 (1): 100117. (Citations: 0)
  2. Wang, S.; Xiao, R.; Chen, Y.; Ye, Y.; He, T.; Yang, Y.; Chen, X.*; Chou, C. K., Anti-tumor necrosis factor therapy in the treatment of systemic autoinflammatory diseases: the responses of innate immune cells. J Leukoc Biol, 2025, 117 (5): qiaf026. (Citations: 0)
  3. Wang, S.; Leung, C.-H.; Chen, X.; Li, P.; Lu, J.; Lu, J.; Hu, Y.; Ung, O. L.; Zheng, Y.; Zhang, W.; Jiang, Z.; Chen, X.*, Mechanism-oriented quality research system for traditional Chinese medicine. SSV, 2025, 55 (4): 607-617. (Citations: 0)
  4. Wang, M.; Wan, Q.; Wang, C.; Jing, Q.; Nie, Y.; Zhang, X.; Chen, X.; Yang, D.; Pan, R.; Li, L.; Zhu, L.; Gui, H.; Chen, S.; Deng, Y.; Chen, T.; Nie, Y., Combinational delivery of TLR4 and TLR7/8 agonist enhanced the therapeutic efficacy of immune checkpoint inhibitors to colon tumor. Mol Cell Biochem, 2025, 480 (1): 445-458. (Citations: 0)
  5. Tan, L.; Tu, Y.; Miao, Z.; Zhao, Y.; Liang, Y.; Zhong, J.; Zhong, R.; Xu, N.; Chen, X.; He, C., Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway. Phytomedicine, 2025, 138: 156429. (Citations: 1)
  6. Luo, H.; She, X.; Zhang, Y.; Xie, B.; Zhang, S.; Li, Q.; Zhou, Y.; Guo, S.; Zhang, S.; Jiang, Y.; Dong, Y.; He, J.; Wang, L.; Zhang, Q.; Zhuang, Y.; Deng, P.; Wang, F.; Liu, J.; Chen, X.*; Nie, H.; He, H., PLIN2 Promotes Lipid Accumulation in Ascites-Associated Macrophages and Ovarian Cancer Progression by HIF1α/SPP1 Signaling. Adv Sci (Weinh), 2025, 12 (12): e2411314. (Citations: 0)
  7. Huang, C.; Lyu, C.; Mok, H. L.; Xu, Y.; Cheng, K. W.; Zhang, C.; Hu, D.; Zhu, L.; Lin, C.; Chen, X.; Tan, H. Y.; Bian, Z., Tolerogenic dendritic cell-mediated regulatory T cell differentiation by Chinese herbal formulation attenuates colitis progression. J Adv Res, 2025, 70: 499-513. (Citations: 1)
  8. Chen, Y.; Jiang, M.; Liao, P.; Yang, Y.; Chen, Z.; Gao, Y.; Wang, Y.; Chou, C. K.; Chen, X.*, miR-125b-5p sensitizes colorectal cancer to anti-PD-L1 therapy by decreasing TNFR2 expression on tumor cells. J Leukoc Biol, 2025: qiaf059. (Citations: 0)
  9. Yusoff, N. N. F. M.; Ahmad, S.; Rahman, W. F. W. A.; Mohamud, R.; Boer, J. C.; Plebanski, M.; Abdullah, B.; Chen, X.; Din, T. A. D. A. T., CD4+Foxp3+Regulatory T-cells in Modulating Inflammatory Microenvironment in Chronic Rhinosinusitis with Nasal Polyps: Progress and Future Prospect. Cytokine, 2024, 178:156557. (Citations: 0)
  10. Tan, L.; Miao, Z.; Zhao, Y.; Liang, Y.; Xu, N.; Chen, X.; Tu, Y.; He, C., Dual regulation of phaseol on osteoclast formation and osteoblast differentiation by targeting TAK1 kinase for osteoporosis treatment. J Adv Res, 2024. (Citations: 0)
  11. Li, P.; Yang, Y.; Wang, Y.; Zheng, J.; Chen, F.; Jiang, M.; Chou, C. K.; Cong, W.; Li, Z.; Chen, X.*, Anti-TNFR2 Antibody-Conjugated PLGA Nanoparticles for Targeted Delivery of Adriamycin in Mouse Colon Cancer. Research (Wash D C)., 2024, 7: 0444. (Citations: 1)
  12. Zhu, L.; Zhang, X.; Chen, X.; Yang, D.; Nie, Y.; Pan, R.; Li, L.; Wang, C.; Gui, H.; Chen, S. H.; Jing, Q.; Wang, M.; Nie, Y., Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M 052 stimulated dendritic cell vaccine in a mouse model of colon cancer. Biochem Bioph Res Co, 2023, 653: 106-114. (Citations: 9)
  13. Yang, Y.; Wang, Q. F.; Zou, H.; Chou, C. K.; Chen, X.*, Exosome-Modified Liposomes Targeted Delivery of Thalidomide to Regulate Treg Cells for Antitumor Immunotherapy. Pharmaceutics, 2023, 15 (4): 1074. (Citations: 5)
  14. Liao, P.; Jiang, M.; Islam, M.; Wang, Y.; Chen, X.*, TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. Front Immunol, 2023, 14: 1097090. (Citations: 7)
  15. Li, P.; Yang, Y.; Yang, X.; Wang, Y.; Chou, C.-K.; Jiang, M.; Zheng, J.; Chen, F.; Chen, X.*, TNFR2 deficiency impairs the growth of mouse colon cancer. Int J of Bio Sci, 2023, 19 (4): 1024. (Citations: 11)
  16. Islam, M. S.; Wang, Z.; Abdel-Mohsen, M.; Chen, X.*; Montaner, L. J., Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID. J Leukoc Biol, 2023, 113 (3): 236-254. (Citations: 16)
  17. He, T.; Chen, Y.; Yang, D.; Islam, M. S.; Chou, C. K.; Liu, J.; Faustman, D. L.; Oppenheim, J. J.; Chen, X.*, TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4 Foxp3 regulatory T cells. Cell Oncol, 2023, 46 (1): 167-177. (Citations: 7)
  18. Geng, C.; Chen, F.; Zheng, J.; Liao, P.; Li, T.; Zhang, X.; Chen, X.*; Chen, J., Rubiginosin B selectively inhibits Treg cell differentiation and enhances anti-tumor immune responses by targeting calcineurin-NFAT signaling pathway. Phytomedicine, 2023, 116: 154898. (Citations: 6)
  19. Chen, Y.; Jiang, M.; Chen, X.*, Therapeutic potential of TNFR2 agonists: a mechanistic perspective. Front Immunol, 2023, 14: 1209188. (Citations: 3)
  20. Chen, X.*; Plebanski, M., Editorial: The role of TNF-TNFR2 signal in immunosuppressive cells and its therapeutic implications, volume II. Front Immunol, 2023, 14: 1227003. (Citations: 1)
  21. Abd Rahman, E. N. S. E.; Irekeola, A. A.; Shueb, R. H.; Lazim, N. M.; Mohamud, R.; Chen, X.; Ghazali, L.; Awang, N. M. S. H.; Haron, A.; Chan, Y. Y., Aberrant frequency of TNFR2-expressing CD4+FoxP3+regulatory T cells in nasopharyngeal carcinoma patients. Cytokine, 2023, 170: 156341. (Citations: 0)
  22. 郑静彬; 杨阳; 陈新*, TNFR2对CD4(+)Foxp3(+)Treg的活化、增殖及功能影响的研究进展. 现代免疫学, 2022, 42 (1): 1-6.
  23. Xi, L.; Lin, Z.; Qiu, F.; Chen, S.; Li, P.; Chen, X.; Wang, Z.; Zheng, Y., Enhanced uptake and anti-maturation effect of celastrol-loaded mannosylated liposomes on dendritic cells for psoriasis treatment. Acta Pharm Sin B, 2022, 12 (1): 339-352. (Citations: 63)
  24. Lambuk, L.; Ahmad, S.; Sadikan, M. Z.; Nordin, N. A.; Kadir, R.; Nasir, N. A. A.; Chen, X.; Boer, J.; Plebanski, M.; Mohamud, R., Targeting Differential Roles of Tumor Necrosis Factor Receptors as a Therapeutic Strategy for Glaucoma. Front Immunol, 2022, 13: 857812. (Citations: 6)
  25. Jiang, M.; Yang, Y.; Niu, L.; Li, P.; Chen, Y.; Liao, P.; Wang, Y.; Zheng, J.; Chen, F.; He, H.; Li, H.; Chen, X.*, MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. J Immunotherapy Cancer, 2022, 10 (11): e005241. (Citations: 17)
  26. Chen, F.; Geng, C.; Zheng, J.; Li, T.; Yang, Y.; Wang, Y.; Li, P.; Jiang, M.; Li, Y.; Chen, J.; Chen, X., 1-Aryl-1,2,3,4-tetrahydro-isoquinolines inhibit TNFR2-mediated proliferative expansion of CD4+Foxp3+ regulatory T cells. Research Square, 2022. (Citations: 62)
  27. Chen, Z.; Zhang, Y.; Wang, M.; Islam, M. S.; Liao, P.; Hu, Y.; Chen, X.*, Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. Int J Biol Sci, 2022, 18 (12): 4629-4641. (Citations: 29)
  28. Chen, S.; Lin, Z.; He, T.; Islam, M. S.; Xi, L.; Liao, P.; Yang, Y.; Zheng, Y.; Chen, X.*, Topical Application of Tetrandrine Nanoemulsion Promotes the Expansion of CD4 Foxp3 Regulatory T Cells and Alleviates Imiquimod-Induced Psoriasis in Mice. Front Immunol, 2022, 13: 800283. (Citations: 9)
  29. Chen, S.; Liao, P.; Xi, L.; Yang, Y.; Wu, W.; Islam, M. S.; Lin, Z.; Zheng, Y.; Chen, X.* ,The therapeutic effect of tacrolimus in a mouse psoriatic model is associated with the induction of myeloid-derived suppressor cells. Rheumatol Immunol Re, 2022, 3 (4): 190-197. (Citations: 3)
  30. Chen, S.; Li, R.; Chen, Y.; Chou, C.; Zhang, Z.; Yang, Y.; Liao, P.; Wang, Q.; Chen, X.*, Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4 Foxp3 regulatory T cells. Biomed Pharmacother, 2022, 151: 113187. (Citations: 15)
  31. Chen, F.; Geng, C.; Chou, C. K.; Zheng, J.; Yang, Y.; Wang, Y.; Li, T.; Li, P.; Chen, J.; Chen, X.*, Distepharinamide, a novel dimeric proaporphine alkaloid from inhibits the differentiation and proliferative expansion of CD4 Foxp3 regulatory T cells. Phytomedicine, 2022, 107: 154482. (Citations: 2)
  32. Yang, Y.; Islam, M. S.; Hu, Y.; Chen, X.*, TNFR2: Role in cancer immunology and immunotherapy. Immunotargets Ther, 2021, 10: 103-122. (Citations: 33)
  33. Wang, Y.; Zheng, J.; Islam, M. S.; Yang, Y.; Hu, Y.; Chen, X.*, The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment. Int J Biol Sci, 2021, 17 (6): 1507-1520. (Citations: 60)
  34. Liu, K.; Gu, Z.; Islam, M. S.; Scherngell, T.; Kong, X.; Zhao, J.; Chen, X.; Hu, Y., Global landscape of patents related to human coronaviruses. Int J Biol Sci, 2021, 17 (6): 1588-1599. (Citations: 28)
  35. Lin, Z.; Xi, L.; Chen, S.; Tao, J.; Wang, Y.; Chen, X.; Li, P.; Wang, Z.; Zheng, Y., Uptake and trafficking of different sized PLGA nanoparticles by dendritic cells in imiquimod-induced psoriasis-like mice model. Acta Pharm Sin B, 2021, 11 (4): 1047-1055. (Citations: 34)
  36. Li, P.; Chen, F.; Zheng, J.; Yang, Y.; Li, Y.; Wang, Y.; Chen, X.*, Cyclophosphamide abrogates the expansion of CD4+ Foxp3+ regulatory T cells and enhances the efficacy of bleomycin in the treatment of mouse B16-F10 melanomas. Cancer Biol Med, 2021, 18 (4): 1010. (Citations: 9)
  37. Jiang, M.; Liu, J.; Yang, D.; Tross, D.; Li, P.; Chen, F.; Alam, M. M.; Faustman, D. L.; Oppenheim, J. J.; Chen, X.*, A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer. Int Immunopharmacol, 2021, 101: 108345. (Citations: 24)
  38. Islam, M. S.; Yang, Y.; Chen, X.*, TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4+Foxp3+ Regulatory T Cells: Implications in the Treatment of Autoimmune Diseases and Cancer. Adv Exp Med Biol, 2021, 1278: 257-272. (Citations: 6)
  39. Chen, S.; Lin, Z.; Xi, L.; Zheng, Y.; Zhou, Q.; Chen, X.*, Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis. J Leukoc Biol, 2021, 110 (6): 1047-1055. (Citations: 11)
  40. Ye, L.; Peng, W.; Niu, Y.; Xiang, X.; Wei, X.; Wang, Z.; Wang, X.; Zhang, S.; Chen, X.*; Zhou, Q., Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. Ann Transl Med, 2020, 8 (24): 1647. (Citations: 23)
  41. Yang, Y.; Islam, M. S.; Wang, J.; Li, Y.; Chen, X.*, Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int J Biol Sci, 2020, 16 (10): 1708-1717. (Citations: 603)
  42. Wang, J.; Jiang, M.; Chen, X.*; Montaner, L. J., Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol, 2020, 108 (1): 17-41. (Citations: 532)
  43. Lyu, L.; Feng, Y.; Chen, X.; Hu, Y., The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. Nat Biotechnol, 2020, 38 (12): 1387-1394. (Citations: 23)
  44. Li, P.; Yang, X.; Yang, Y.; He, H.; Chou, C. K.; Chen, F.; Pan, H.; Liu, L.; Cai, L.; Ma, Y.; Chen, X.*, Synergistic effect of all-trans-retinal and triptolide encapsulated in an inflammation-targeted nanoparticle on collagen-induced arthritis in mice. J Control Release, 2020, 319: 87-103. (Citations: 65)
  45. He, T.; Yang, D.; Li, X.; Jiang, M.; Islam, M. S.; Chen, S.; Chen, Y.; Yang, Y.; Chou, C. K.; Trivett, A. L.; Oppenheim, J. J.; Chen, X.*, Inhibition of two-pore channels in antigen-presenting cells promotes the expansion of TNFR2-expressing CD4+Foxp3+ regulatory T cells. Sci Adv, 2020, 6 (40): eaba6584. (Citations: 18)
  46. Chou, C. K.; Chen, X.*, Preferential Expansion of CD4+Foxp3+ Regulatory T Cells (Tregs) In Vitro by Tumor Necrosis Factor. Methods Mol Biol, 2020, 2111: 71-78. (Citations: 1)
  47. Azid, N. A.; Ahmad, S.; Boer, J. C.; Al-Hatamleh, M. A. I.; Mohammad, N.; Mohd Ashari, N. S.; Tan, H. T.; Chen, X.; Plebanski, M.; Mohamud, R., A profile of TNFR2+ regulatory T cells and CD103+ dendritic cells in the peripheral blood of patients with asthma. Hum Immunol, 2020, 81 (10-11): 634-643. (Citations: 2)
  48. 杨阳; 陈新, 中药及其活性成分对肿瘤相关调节性T细胞抑制作用研究. 自然杂志， 2019, 41 (4): 261-265.
  49. Zou, H.; He, T.; Chen, X.*, Tetrandrine inhibits differentiation of proinflammatory subsets of T helper cells but spares de novo differentiation of iTreg cells. Int Immunopharmacol, 2019, 69: 307-312. (Citations: 31)
  50. Zhu, L.; Li, P.; Gao, D.; Liu, J.; Liu, Y.; Sun, C.; Xu, M.; Chen, X.; Sheng, Z.; Wang, R.; Yuan, Z.; Cai, L.; Ma, Y.; Zhao, Q., pH-sensitive loaded retinal/indocyanine green micelles as an “all-in-one” theranostic agent for multi-modal imaging in vivo guided cellular senescence-photothermal synergistic therapy. Chem Commun (Camb), 2019, 55 (44): 6209-6212. (Citations: 25)
  51. Ye, L.; Peng, W.; Niu, Y.; Wei, X.; Wang, Z.; Meng, D.; Wang, X.; Chen, X.; Zhou, Q., TNF Receptor Type II Is Critical to the Expansion and Suppressive Function of Regulatory T Cells in Malignant Pleural Effusion from Lung Cancer Patients. SSRN, 2019. (Citations: 0)
  52. He, J.; Li, R.; Chen, Y.; Hu, Y.; Chen, X.*, TNFR2-expressing CD4+Foxp3+ regulatory T cells in cancer immunology and immunotherapy. Prog Mol Biol Transl Sci, 2019, 164: 101-117. (Citations: 17)
  53. Chen, Y.; Chen, X.*, Ancient herbal component may be a novel therapeutic for gouty arthritis. J Leukoc Biol, 2019, 105 (1): 7-9. (Citations: 6)
  54. Al-Hatamleh, M. A. I.; E, A. R. E.; Boer, J. C.; Ferji, K.; Six, J. L.; Chen, X.; Elkord, E.; Plebanski, M.; Mohamud, R., Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor-An Opportunity for Cancer Treatment. Cells, 2019, 9 (1): 33. (Citations: 17)
  55. Al-Hatamleh, M. A. I.; Ahmad, S.; Boer, J. C.; Lim, J.; Chen, X.*; Plebanski, M.; Mohamud, R., A Perspective Review on the Role of Nanomedicine in the Modulation of TNF-TNFR2 Axis in Breast Cancer Immunotherapy. J Oncol, 2019, 2019: 6313242. (Citations: 27)
  56. Chen, X.*; Plebanski M., Editorial: The Role of TNF-TNFR2 Signal in Immunosuppressive Cells and Its Therapeutic Implications. Front Immunol, 2019, 6(10): 2126. (Citations: 6)
  57. Zou, H.; Li, R.; Hu, H.; Hu, Y.; Chen, X.*, Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. Front Immunol, 2018, 9: 594. (Citations: 47)
  58. Shaikh, F.; He, J.; Bhadra, P.; Chen, X.*; Siu, S. W. I., TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders. Front Immunol, 2018, 9: 1382. (Citations: 17)
  59. Nie, Y.; He, J.; Shirota, H.; Trivett, A. L.; Yang; Klinman, D. M.; Oppenheim, J. J.; Chen, X.*, Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Sci Signal, 2018, 11 (511): eaan0790. (Citations: 56)
  60. Liu, S.; Chen, X.*, Dietary therapy may be sufficient for type 1 diabetes treatment. Cell mol Immunol, 2018, 15 (2): 85-87. (Citations: 7)
  61. He, T.; Yang, D.; Chen, X.; Oppenheim, J. J., Tetrandrine (TET) up-regulated mTNF expression on dendritic cells and consequently induces TNFR2 mediated proliferation of Tregs. J Immunol, 2018, 200 (Supplement_1): 47.19. (Citations: 1)
  62. He, T.; Liu, S.; Chen, S.; Ye, J.; Wu, X.; Bian, Z.; Chen, X.*, The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4+Foxp3+Regulatory T Cells. Front Immunol, 2018, 9: 1556. (Citations: 36)
  63. Chen, X.; Li, P.; Yang, X.; Miao, X.; Luo, H., Tumor necrosis factor receptor II (TNFR2) promotes the growth of mouse CT26 colon cancer. J Immunol, 2018, 200 (1_Supplement): 178.7. (Citations: 3)
  64. Chen, K.; Singh, V. K.; Tang, P.; Bao, Z.; He, T.; Xiang, Y.; Gong, W.; Yoshimura, T.; Le, Y.; Tessarollo, L.; Chen, X.; Wang, J. M., Deficiency in Fpr2 results in reduced numbers of Lin-cKit+Sca1+ myeloid progenitor cells. J Biol Chem, 2018, 293 (35): 13452-13463. (Citations: 9)
  65. Ahmad, S.; Azid, N. A.; Boer, J. C.; Lim, J.; Chen, X.; Plebanski, M.; Mohamud, R., The Key Role of TNF-TNFR2 Interactions in the Modulation of Allergic Inflammation: A Review. Front Immunol, 2018, 9: 2572. (Citations: 77)
  66. Yin, T.; Kong, X.; Wang, Y.; Chen, X.; Hu, Y.; Shao, R., Collaboration networks for R&D of monoclonal antibodies: An analysis based on pipeline projects. USCIPI, 2017. (Citations: 0)
  67. Sun, L.; Liu, Z.; Wang, L.; Cun, D.; Tong, H.; Yan, R.; Chen, X.; Wang, R.; Zheng, Y., Enhanced topical penetration, system exposure and anti-psoriasis activity of two particle-sized, curcumin-loaded PLGA nanoparticles in hydrogel. J Control Release, 2017, 254: 44-54. (Citations: 154)
  68. Nie, Y.; Yang, D.; Trivett, A.; Han, Z.; Xin, H.; Chen, X.; Oppenheim, J. J., Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors. Sci Rep, 2017, 7 (1): 14186. (Citations: 30)
  69. Li, P.; Zheng, Y.; Chen, X.*, Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front Pharmacol, 2017, 8: 460. (Citations: 256)
  70. Lai, Y.; Wang, R.; Chen, X.; Tang, D.; Hu, Y.; Cai, J.; Zhang, Q.; Hu, H., Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Hum Vaccin Immunother, 2017, 13(6): 1-10. (Citations: 16)
  71. Kong, X.; Zhang, Q.; Lai, Y.; Hu, H.; Chen, X.; Hu, Y., Global patent landscape of programmed cell death 1: implications of the rapid expansion. Expert Opin Ther Pat, 2018, 28(1): 69-80. (Citations: 4)
  72. Chen, X.*; Oppenheim, J. J., Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer. Sci Signal, 2017, 10 (462): 1-3. (Citations: 62)
  73. Chen, X.*; He, T., The p38 MAPK inhibitor SB203580 abrogates TNF-Inediated expansion of regulatory T cells. J Immunol, 2017, 198 (1): 4. (Citations: 36)
  74. Zaragoza, B.; Chen, X.; Oppenheim, J. J.; Baeyens, A.; Gregoire, S.; Chader, D.; Gorochov, G.; Miyara, M.; Salomon, B. L., Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat Med, 2016, 22 (1): 16-7. (Citations: 89)
  75. Lee-Chang, C.; Bodogai, M.; Moritoh, K.; Chen, X.; Wersto, R.; Sen, R.; Young, H. A.; Croft, M.; Ferrucci, L.; Biragyn, A., Aging Converts Innate B1a Cells into Potent CD8+ T Cell Inducers. J Immunol, 2016, 196 (8): 3385-97. (Citations: 25)
  76. He, J.; He, Z.; Chen, X.*, Effects of Chinese medicinal components on chemokine receptors: theory, results and methodology. Evidence-based Research Methods for Chinese Medicine, 2016: 187-197. (Citations: 2)
  77. Chen, X.*; Oppenheim, J. J., Therapy: Paradoxical effects of targeting TNF signalling in the treatment of autoimmunity. Nat Rev Rheumatol, 2016, 12 (11): 625-626. (Citations: 18)
  78. Chen, X.*; Oppenheim, J. J., Tetrandrine (TET), an immunosuppressive component of Chinese herb, induces tolerogenic dendritic cells and consequently expands regulatory T cells. J Immunol, 2016, 196: 2. (Citations: 4)
  79. Chen, X.; Nie, Y.; Xiao, H.; Bian, Z.; Scarzello, A. J.; Song, N. Y.; Anna, T. L.; Yang, D.; Oppenheim, J. J., TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. Sci Rep, 2016, 6: 32834. (Citations: 39)
  80. Yoshimura, T.; Liu, M.; Chen, X.; Li, L.; Wang, J. M., Crosstalk between Tumor Cells and Macrophages in Stroma Renders Tumor Cells as the Primary Source of MCP-1/CCL2 in Lewis Lung Carcinoma. Front Immunol, 2015, 6: 332. (Citations: 25)
  81. Yan, F.; Du, R.; Wei, F.; Zhao, H.; Yu, J.; Wang, C.; Zhan, Z.; Ding, T.; Ren, X.; Chen, X.*; Li, H., Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. Cancer Immunol Immunother, 2015, 64 (11): 1475-85. (Citations: 66)
  82. Hamano, R.; Wu, X.; Wang, Y.; Oppenheim, J. J.; Chen, X.*, Characterization of MT-2 cells as a human regulatory T cell-like cell line. Cell mol Immunol, 2015, 12 (6): 780-2. (Citations: 32)
  83. Geng, X.; Kong, X.; Hu, H.; Chen, J.; Yang, F.; Liang, H.; Chen, X.; Hu, Y., Research and development of therapeutic mAbs: An analysis based on pipeline projects. Hum Vaccin Immunother, 2015, 11(12): 2769-76. (Citations: 26)
  84. Chen, X.; Tang, Z.; Shi, Z.; Lu, J.; Su, H.; Chen, X.; Wang, Y., Current topics on cancer biology and research strategies for anti-cancer traditional Chinese medicine. China J Chin Mater Med, 2015, 40 (17): 3416-22. (Citations: 1)
  85. Chen, X.*; Willette-Brown, J.; Wu, X.; Hu, Y.; Howard, O. M.; Oppenheim, J. J., IKKalpha is required for the homeostasis of regulatory T cells and for the expansion of both regulatory and effector CD4 T cells. Faseb J 2015, 29 (2): 443-54. (Citations: 42)
  86. Salomon, B.; Zaragoza, B.; Chen, X.; Oppenheim, J. J.; Baeyens, A.; Grégoire, S.; Chader, D.; Miyara, M., Human Treg cell suppressive assays. Protoc Exch, 2015. (Citations: 0)
  87. Zhou, Q.; Hu, Y.; Howard, O. M.; Oppenheim, J. J.; Chen, X.*, In vitro generated Th17 cells support the expansion and phenotypic stability of CD4+Foxp3+ regulatory T cells in vivo. Cytokine, 2014, 65 (1): 56-64. (Citations: 18)
  88. Weiss, J. M.; Subleski, J. J.; Back, T.; Chen, X.; Watkins, S. K.; Yagita, H.; Sayers, T. J.; Murphy, W. J.; Wiltrout, R. H., Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/alphaCD40 therapy. J Immunol, 2014, 192 (12): 5821-9. (Citations: 47)
  89. Wei, F.; Yang, D.; Tewary, P.; Li, Y.; Li, S.; Chen, X.; Howard, O. M. Z.; Bustin, M.; Oppenheim, J. J., The Alarmin HMGN1 Contributes to Antitumor Immunity and Is a Potent Immunoadjuvant. Cancer Res, 2014, 74 (21): 5989-5998. (Citations: 51)
  90. Hu, Y.; Xiao, H.; Shi, T.; Oppenheim, J. J.; Chen, X.*, Progranulin promotes tumour necrosis factor-induced proliferation of suppressive mouse CD4+ Foxp3+ regulatory T cells. Immunol, 2014, 142 (2): 193-201. (Citations: 29)
  91. Chen, X.*; Yang, Y.; Zhou, Q.; Weiss, J. M.; Howard, O. Z.; McPherson, J. M.; Wakefield, L. M.; Oppenheim, J. J., Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One, 2014, 9 (1): e85398. (Citations: 36)
  92. Chen, X.*; Xiao, H.; Howard, O. M. Z.; Oppenheim, J., TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis. J Immunol, 2014, 192 (Supplement_1): 115.1. (Citations: 39)
  93. Chen, X.*; Wakefield, L. M.; Oppenheim, J. J., Synergistic antitumor effects of a TGFβ inhibitor and cyclophosphamide. Oncoimmunology 2014, 3: e28247. (Citations: 7)
  94. Chen, X.*; Oppenheim, J. J., Th17 cells and Tregs: unlikely allies. J Leukoc Biol, 2014, 95 (5): 723-731. (Citations: 74)
  95. Chen, X.*; Wu, X.; Zhou, Q.; Howard, O. M.; Netea, M. G.; Oppenheim, J. J., TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol, 2013, 190 (3): 1076-84. (Citations: 234)
  96. Chen, X.*; Willette-Brown, J.; Wu, X.; Howard, O. M. Z.; Hu, Y.; Oppenheim, J., IKKalpha is critical for the maintenance of a normal pool of regulatory T cells and for the expansion of both regulatory and effector T cells (P1095). J Immunol, 2013, 190 (Supplement_1): 121.19. (Citations: 0)
  97. Weiss, J. M.; Subleski, J. J.; Back, T.; Chen, X.; Watkins, S. K.; Yagita, H.; Sayers, T. J.; Murphy, W. J.; Wiltrout, R. H., Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/aCD40 Therapy. J Immunol, 2014, 192(12): 5821-9. (Citations: 47)
  98. Chen, X.*; Wu, X.; Howard, O. M. Z.; Oppenheim, J., Interaction of TNF and TNFR2 stabilizes the phenotype and function of CD4+FoxP3+ regulatory T cells in the inflammatory environment. J Immunol, 2012, 188 (1_Supplement): 179.16. (Citations: 0)
  99. Hamano, R.; Huang, J.; Yoshimura, T.; Oppenheim, J. J.; Chen, X.*, TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4-1BB and OX40. Eur J Immunol, 2011, 41 (7): 2010-20. (Citations: 83)
  100. Griessl, S.; Chen, X.; Oppenheim, J.; Maennel, D., The Dual Role of TNF On T Cell Activation. Adv TNF Family Res, 2011, 691: 692-693. (Citations: 0)
  101. Chertov, O.; Zhang, N.; Chen, X.; Oppenheim, J. J.; Lubkowski, J.; McGrath, C.; Sowder, R. C., 2nd; Crise, B. J.; Malyguine, A.; Kutzler, M. A.; Steele, A. D.; Henderson, E. E.; Rogers, T. J., Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture. PLoS One, 2011, 6 (1): e14474. (Citations: 5)
  102. Chen, X.*; Oppenheim, J. J., Comment on “Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis”. J Immunol, 2011, 187 (4): 1527. (Citations: 0)
  103. Chen, X.*; Oppenheim, J. J., Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells. Int Immunopharmacol, 2011, 11 (10): 1489-96. (Citations: 92)
  104. Chen, X.*; Oppenheim, J. J., The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4+ FoxP3+ regulatory T cells. Immunology, 2011, 133 (4): 426-33. (Citations: 64)
  105. Chen, X.; Oppenheim, J. J., Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett, 2011, 585 (23): 3611-8. (Citations: 81)
  106. Chen, X.*; Subleski, J. J.; Hamano, R.; Howard, O. M.; Wiltrout, R. H.; Oppenheim, J. J., Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood. Eur J Immunol, 2010, 40 (4): 1099-106. (Citations: 174)
  107. Chen, X.*; Oppenheim, J. J., TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun, 2010, 11: 119-34. (Citations: 94)
  108. Chen, X.*; Hamano, R.; Subleski, J. J.; Hurwitz, A. A.; Howard, O. M.; Oppenheim, J. J., Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells. J Immunol, 2010, 185 (1): 174-82. (Citations: 112)
  109. Chen, X.*, Maturation and Activation of Dendritic Cells by Botanicals Used in Traditional Chinese Medicine: Role in Immune Enhancement. Dietary Components and Immune Function, 2010: 497-514. (Citations: 1)
  110. Weiss, J. M.; Back, T. C.; Scarzello, A. J.; Subleski, J. J.; Hall, V. L.; Stauffer, J. K.; Chen, X.; Micic, D.; Alderson, K.; Murphy, W. J.; Wiltrout, R. H., Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A, 2009, 106 (46): 19455-60. (Citations: 53)
  111. Chen, X.*; Oppenheim, J., Regulatory T Cells, Th17 Cells, and TLRs: Crucial roles in Inflammation, autoimmunity, and cancer. Pathways, Cover Story (10), 2009, 6. (Citations: 0)
  112. Mazzucchelli, R.; Hixon, J. A.; Spolski, R.; Chen, X.; Li, W. Q.; Hall, V. L.; Willette-Brown, J.; Hurwitz, A. A.; Leonard, W. J.; Durum, S. K., Development of regulatory T cells requires IL-7Ralpha stimulation by IL-7 or TSLP. Blood, 2008, 112 (8): 3283-92. (Citations: 105)
  113. Li, J.; Chen, X.; Lin, H. S.; Oppenheim, J. J.; Howard, O. M. Z., Inhibitory effect of Sheng Qi Formula (SQF) on Gr-1+ CD11b+ myeloid immunosuppressor cells (MIC) in the 4T1 murine mammary cancer model. Cancer Res, 2008, 68 (9_Supplement): 5336. (Citations: 3)
  114. Howard, D. N. M.; Oppenheim, J. J.; Chen, X.; Subleski, J. J.; Kopf, H.; Zack, O., This information is current as Regulatory Cells. J Immunol, 2008, 180: 6467-6471. (Citations: 0)
  115. Hodge, D. L.; Berthet, C.; Subleski, J.; Bere, W.; Chen, X.; Coppola, V.; Buschman, M.; Wolfe, T.; Shuggi, I.; Young, H. A., IFN-γ 3’untranslated region AU-RICH element-deleted mice have altered immune structure and function. Cytokine, 2008, 43 (3): 313 (Citations: 0)
  116. Chen, X.*; Subleski, J. J.; Kopf, H.; Howard, O. M.; Mannel, D. N.; Oppenheim, J. J., Expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol, 2008, 180 (10): 6467-71. (Citations: 273)
  117. Murakami, T.; Chen, X.; Hase, K.; Sakamoto, A.; Nishigaki, C.; Ohno, H., Splenic CD19−CD35+B220+ cells function as an inducer of follicular dendritic cell network formation. Blood, 2007, 110 (4): 1215-1224. (Citations: 21)
  118. Kopf, H.; de la Rosa, G. M.; Howard, O. M.; Chen, X.*, Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol, 2007, 7 (13): 1819-24. (Citations: 222)
  119. Kim, J.-Y.; Kim, H.-J.; Hurt, E. M.; Chen, X.; Howard, O. M. Z.; Farrar, W. L., Functional and genomic analyses of FOXP3-transduced Jurkat-T cells as regulatory T (Treg)-like cells. Biochem Bioph Res Co, 2007, 362 (1): 44-50. (Citations: 19)
  120. Howard, O. Z.; Oppenheim, J. J.; Chen, X.*, Biological regulators of CD4+ CD25+ FOXP3+ regulatory T-cells. Cytokine, 2007, 39(1): 16. (Citations: 0)
  121. Hodge, D. L.; Berthet, C.; Subleski, J.; Pascal, V.; Bere, W.; Chen, X.; Buschman, M.; Wolfe, T.; Young, H. A., Challenging evolution: eliminating the IFN-gamma 3 ARE effects T cell homenstasis. Cytokine, 2007, 39(1): 15-16. (Citations: 0)
  122. Hodge, D.; Berthet, C.; Subleski, J.; Pascal, V.; Bere, W.; Chen, X.; Buschman, M.; Wolfe, T.; Young, H., Phenotypic changes in ifn-gamma 3’UTR are knock out mice. J Interf Cytok Res, 2007, 27(8): 714-714. (Citations: 0)
  123. Chen, X.*; Howard, O. M.; Oppenheim, J. J., Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells. J Immunol, 2007, 178 (10): 6123-9. (Citations: 83)
  124. Chen, X.*; Baumel, M.; Mannel, D. N.; Howard, O. M.; Oppenheim, J. J., Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol, 2007, 179 (1): 154-61. (Citations: 452)
  125. Chen, X.*; Yang, L.; Howard, O. M.; Oppenheim, J. J., Dendritic cells as a pharmacological target of traditional Chinese medicine. Cell Mol Immunol, 2006, 3 (6): 401-10. (Citations: 28)
  126. Chen, X.*; Winkler-Pickett, R. T.; Carbonetti, N. H.; Ortaldo, J. R.; Oppenheim, J. J.; Howard, O. M. Z., Pertussis toxin as an adjuvant suppresses the number and function of CD4+CD25+ T regulatory cells. Eur J Immunol, 2006, 36 (3): 671-680. (Citations: 90)
  127. Chen, X.*; Oppenheim, J. J.; Winkler-Pickett, R. T.; Ortaldo, J. R.; Howard, O. M. Z., Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol, 2006, 36 (8): 2139-2149. (Citations: 182)
  128. 陈新, 来自 NIH 的中医药研究中药作用于趋化因子及其受体的潜在治疗学意义. 亚太传统医药, 2005, 3: 67-68.
  129. 曾广仙; 陈新; 刘俊英; 衷学军; 代丽红; 赵璐; 沈关心, 加味玉屏风散对创伤应激小鼠细胞免疫功能的影响. 中医杂志, 2005, 46 (5): 3.
  130. 曾广仙; 刘俊英; 熊金蓉; 代丽红; 赵璐; 杨燕萍; 陈新; 沈关心, 加味玉屏风散对创伤应激小鼠CD4+CD25+调节性T细胞影响的实验研究. 中华微生物学和免疫学杂志, 2005, 25 (1): 69-69.
  131. Krakauer, T.; Chen, X.; Howard, O. M. Z.; Young, H. A., Triptolide Attenuates Endotoxin- and Staphylococcal Exotoxin-Induced T-Cell Proliferation and Production of Cytokines and Chemokines. Immunophar Immunot, 2005, 27 (1): 53-66. (Citations: 40)
  132. Howard, O. M. Z.; Dong, H. F.; Su, S. B.; Caspi, R. R.; Chen, X.; Plotz, P.; Oppenheim, J. J., Autoantigens signal through chemokine receptors: uveitis antigens induce CXCR3- and CXCR5-expressing lymphocytes and immature dendritic cells to migrate. Blood, 2005, 105 (11): 4207-4214. (Citations: 32)
  133. Chen, X.*; Oppenheim, J. J.; Howard, O. M. Z., BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25− responder T cells than C57BL/6 mice. J Leukoc Biol, 2005, 78 (1): 114-121. (Citations: 102)
  134. Chen, X.*; Murakami, T.; Oppenheim, J. J.; Howard, O. M., Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood, 2005, 106 (7): 2409-16. (Citations: 61)
  135. Chung, I. Y.; Dong, H. F.; Zhang, X.; Hassanein, N. M.; Howard, O. M.; Oppenheim, J. J.; Chen, X., Effects of IL-7 and dexamethasone: induction of CD25, the high affinity IL-2 receptor, on human CD4+ cells. Cell Immunol, 2004, 232 (1-2): 57-63. (Citations: 13)
  136. Chen, X.*; Oppenheim, J. J.; Howard, O. M., Chemokines and chemokine receptors as novel therapeutic targets in rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. Cell Mol Immunol, 2004, 1 (5): 336-42. (Citations: 39)
  137. Chen, X.; Murakami, T.; Oppenheim, J. J.; Howard, O. M. Z., Differential response of murine CD4+CD25+ and CD4+CD25– T cells to dexamethasone-induced cell death. Eur J Immunol, 2004, 34 (3): 859-869. (Citations: 160)
  138. Chen, X.; Krakauer, T.; Oppenheim, J. J.; Howard, O. M., Yin zi huang, an injectable multicomponent chinese herbal medicine, is a potent inhibitor of T-cell activation. J Altern Complement Med, 2004, 10 (3): 519-26. (Citations: 22)
  139. 曾广仙; 陈新; 刘俊英; 沈关心; 熊金蓉, 加味玉屏风汤对创伤应激小鼠IL-2与IL-2R基因表达的影响. 实用临床医学（湖北）, 2003, 17 (2): 2.
  140. Krakauer, T.; Chen, X.; Zack Howard, O. M.; Young, H. A., RNase Protection Assay for the Study of the Differential Effects of Therapeutic Agents in Suppressing Staphylococcal Enterotoxin B-Induced Cytokines in Human Peripheral Blood Mononuclear Cells. Methods Mol Biol, 2003, 214: 151-64. (Citations: 0)
  141. Chen, X.; Yang, L.; Zhang, N.; Turpin, J. A.; Buckheit, R. W.; Osterling, C.; Oppenheim, J. J.; Howard, O. M., Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2003, 47 (9): 2810-6. (Citations: 188)
  142. Chen, X.; Beutler, J. A.; McCloud, T. G.; Loehfelm, A.; Yang, L.; Dong, H. F.; Chertov, O. Y.; Salcedo, R.; Oppenheim, J. J.; Howard, O. M., Tannic acid is an inhibitor of CXCL12 (SDF-1alpha)/CXCR4 with antiangiogenic activity. Clin Cancer Res, 2003, 9 (8): 3115-23. (Citations: 86)
  143. 杨燕萍; 段登志; 胡冬根; 陈新; 未炎; 李小慧, 加味玉屏风汤对小鼠胸腺细胞凋亡的抑制作用. 中国中西医结合杂志 2002, 22 (9): 3.
  144. Chen, X.; Yang, L.; Oppenheim, J. J.; Howard, M. Z., Cellular pharmacology studies of shikonin derivatives. Phytother Res, 2002, 16 (3): 199-209. (Citations: 369)
  145. Chen, X.; Mellon, R. D.; Yang, L.; Dong, H.; Oppenheim, J. J.; Howard, O. M., Regulatory effects of deoxycholic acid, a component of the anti-inflammatory traditional Chinese medicine Niuhuang, on human leukocyte response to chemoattractants. Biochem Pharmacol, 2002, 63 (3): 533-41. (Citations: 35)
  146. Chen, X.; Oppenheim J. J.; Howard O. M. S., A component of anti-inflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1. Int Immunopharmacol, 2001, 1 (2): 229-36. (Citations: 60)
  147. Chen, X.*; Howard, O. M.; Yang, X.; Wang, L.; Oppenheim, J. J.; Krakauer, T., Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function. Life Sci, 2002, 70 (24): 2897-913. (Citations: 59)
  148. 杨燕萍; 胡冬根; 陈新; 朱炎; 胡作为, 黄芪多糖对小鼠胸腺细胞凋亡的调节作用. 中华微生物学和免疫学杂志, 2001, 21 (6): 1.
  149. 杨燕萍; 胡冬根; 陈新, 黄芪多糖和加味玉屏风汤对小鼠胸腺细胞凋亡抑制作用的比较. 湖北中医学院学报, 2001, 003 (004): 34-35.
  150. 陈新, 加味玉屏风汤及黄芪多糖对胸腺细胞凋亡影响的实验研究. 湖北中医学院, 湖北中医药大学, 2000.
  151. Yang, D.; Chen, Q.; Stoll, S.; Chen, X.; Howard, O. M.; Oppenheim, J. J., Differential regulation of responsiveness to fMLP and C5a upon dendritic cell maturation: correlation with receptor expression. J Immunol, 2000, 165 (5): 2694-702. (Citations: 59)
  152. Chen, X.; Yang, L.; Zeng, G.; Shen, G., The regulatory action of the modified Yu Ping Feng Tang on cellular immunity in mice under amputation-induced stress. J Tradit Chin Med, 2000, 20 (4): 302-6. (Citations: 3)
  153. Chen, X.; Yang, D.; Shen, W.; Dong, H. F.; Wang, J. M.; Oppenheim, J. J.; Howard, M. Z., Characterization of chenodeoxycholic acid as an endogenous antagonist of the G-coupled formyl peptide receptors. Inflamm Res, 2000, 49 (12): 744-55. (Citations: 52)
  154. 陈新; 杨路; 夏志道, 玉屏风颗粒剂对手术患者免疫功能调节作用的临床研究. 中药新药与临床药理, 1999, 10 (4): 199-202.
  155. 杨路; 陈新, 鼻敏停治疗过敏性鼻炎疗效观察. 中国中医药信息杂志 1999, 6 (3): 34-34.
  156. 陈新; 杨路; 白云, 加味玉屏风对截肢应激大鼠血浆ACTH及皮质酮的影响. 河北中西医结合杂志, 1998, 7 (7): 2.
  157. 陈新; 杨路; 曾广仙; 沈关心, 加味玉屏风汤对截肢应激小鼠细胞免疫功能的调节作用. 中医杂志, 1998, 39 (12): 3.
  158. 陈新; 杨路; 夏志道; 罗怀灿; 杨述华; 李进, 加味玉屏风冲剂对手术患者免疫功能的调节作用. 中国中医药信息杂志, 1998, 5 (7): 22-23.
  159. 陈新; 杨路, 吴国祥验案四则. 湖北中医杂志, 1998, 04: 48-48.
  160. 陈新; 区永欣; 陈洁文, 亚急性风寒环境刺激对小鼠胸腺的影响及其机理探讨. 中国中医药科技, 1998, 5 (3): 2.
  161. 陈新; 刘菊芳; 桂耀庭; 张永锋, 补肾调肝敛乳方对泌乳素分泌影响的动物实验研究. 中国实验方剂学杂志, 1998, 4 (3): 3.
  162. 陈新, 亚急性风寒环境刺激对小鼠免疫功能影响. 中国中医基础医学杂志, 1998, 4 (3): 3.
  163. 卢亮; 陈新; 夏洪生, 对我院近五年发表论文的回顾与分析. 深圳中西医结合杂志, 1998, 8 (2): 42-42.
  164. 区永欣; 王洪琪; 邝杰钊; 吴弥漫; 陈新; 温伟强; 陈革新; 杨培鑫; 温素萍; 傅杰英, 卫气病理生理研究. 医学研究通讯, 1998, 12: 15-16.
  165. 陈新; 白云; 杨路, 加味玉屏风汤及黄芪多糖对应激小鼠应激激素及巨噬细胞功能的调节作用, 世界中西医结合大会, 1997.
  166. 陈新; 杨路; 白云, 加味玉屏风汤对截肢应激小鼠巨噬细胞功能的调节作用. 中医研究, 1997, 10 (6): 4.
  167. 刘菊芳; 陈新, 中医药治疗高泌乳素血症的研究进展. 中国医药学报, 1997.
  168. 陈新; 张永峰, 加味玉屏风汤对应激及激素注射小鼠细胞免疫功能的影响. 中国实验临床免疫学杂志, 1996, 3: 42-44.
  169. 李伯南; 陈新, 加味玉屏风散对手术应激小鼠胸腺超微结构的影响. 中国病理生理杂志, 1996, 12 (2): 178-180.
  170. 刘菊芳, 陈新, 桂耀庭, 补肾调肝敛乳方治疗高泌乳素血症的实验研究. 中药新药与临床药理, 1996, 7 (2): 3.
  171. 陈新; 陈峰, 环境寒冷因素对免疫功能的影响. 深圳医学信息 1993, 2: 2.
  172. 陈新; 区永欣, 玉屏风散对人工风寒气象环境介导小鼠免疫抑制的预防作用. 中国实验临床免疫学杂志, 1993, 5 (5): 4.
  173. 陈新; 区永欣, 玉屏风散对风寒因素介导小鼠巨噬细胞免疫功能抑制的预防作用. 实用中西医结合杂志, 1993, 6 (9): 548-549.
  174. 陈新; 区永欣, 人工风寒环境对小鼠单核巨噬细胞系统吞噬功能的影响. 中国中西医结合杂志, 1993, 013 (012): 739-740.
  175. 陈新, PMφ释放H_2O_2量测定方法的改进及其在中医免疫药理研究中的应用. 广西中医药, 1993, 16 (5): 2.
  176. 杨路; 陈新, 关于六淫概念的讨论. 湖北中医杂志, 1993, 15 (4): 2.
  177. Chen, X.; Ou, Y. X.; Chen, J. W., Sequential observation on the influence of artificial wind-cold environment to immunologic function of mononuclear phagocytic system in mice. Chin J Integr Med, 1993, 13 (12): 739-40, 710. (Citations: 0)

  • Licensed Doctor of Traditional Chinese Medicine (Health Bureau, Macau SAR, Oct 23, 2019, license No. W/369/2019)
  • Licensed Acupuncturist. The Board of Acupuncture, the State of Maryland, USA. (July 2004~present, license No. U01359)
  • Diplomate in Acupuncture, National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM), USA. (2003-)
  • Qualification for Deputy Chief Physician in Traditional Chinse Medicine. Guagndong Province Technical Cadre Bureau. (Dec 30, 1993. No. 047304)

  • Member, The American Association of Immunologists
  • Member, Society of Leukocyte Biology
  • Vice Chair, Chinese Medicine Immunology Committee, Chinese Society of Immunology
  • Member, China Association of Chinese Medicine
  • Member, Asia-Pacific Association of Medicine and Bio-Immunology
  • Member, International Society of Chinese Medicine

• Outstanding research awards issued by Provincial Government of Guangdong and Municipal Government of Shenzhen between 1991~1998.
• Outstanding Achievement Award (SAIC-Frederick, Inc., 2007)
• US National Cancer Institute Director’s Intramural Innovation Award (2010)
• SLB (Society for Leukocyte Biology, USA) Honorary Lifetime Member Award (2025)